Pacira BioSciences, Inc. is a biopharmaceutical company focused on the development and commercialization of non opioid pain therapies. The firm markets three approved products: EXPAREL a long acting local analgesic for post surgical pain, ZILRETTA an extended release intra articular corticosteroid for osteoarthritis knee pain, and iovera° a handheld device that delivers controlled cold to nerves to provide drug free pain relief. In addition to its commercial portfolio the company advances a pipeline that includes PCRX 201 a gene therapy candidate targeting osteoarthritis and other early stage programs built on its high capacity adenovirus platform. The firm is headquartered in Brisbane California and operates manufacturing sites in San Diego California and partners with third party manufacturers for certain components. Pacira BioSciences, Inc. aims to reduce reliance on opioids by offering effective non opioid alternatives for patients and healthcare providers.

Revenue is generated primarily from product sales of EXPAREL ZILRETTA and iovera°. In the fiscal year ended December 31 2025 EXPAREL net product sales were 575.1 million dollars representing 79 percent of total revenue. ZILRETTA net product sales were 116.6 million dollars and iovera° net product sales were 24.2 million dollars for the same period. The company relies on a small group of large wholesalers to distribute its products to end users. McKesson Drug Company Cardinal Health Inc. and AmerisourceBergen Health Corporation each accounted for 31 percent 26 percent and 22 percent of total revenue respectively in 2025. These wholesalers operate drop ship programs that deliver EXPAREL directly to hospitals ambulatory surgery centers and physician offices without taking physical possession of the goods. Additional revenue comes from sales of ZILRETTA and iovera° through the same distribution channel. The firm also earns modest income from licensing agreements and royalties but product sales constitute the overwhelming majority of its top line.

Pacira BioSciences, Inc. occupies a distinctive niche in the broader pain management market as a provider of non opioid therapies that address postoperative and osteoarthritis pain. Its main competitors include generic opioid manufacturers, companies selling generic bupivacaine formulations, and makers of traditional non steroidal anti inflammatory drugs such as ketorolac and ibuprofen injections. In the osteoarthritis space ZILRETTA competes with immediate release corticosteroid injections and hyaluronic acid products while iovera° faces competition from other cryotherapy devices and radiofrequency ablation systems offered by firms like Avanos Medical. Despite this competition Pacira BioSciences, Inc. benefits from several competitive advantages. Its flagship product EXPAREL is the only long acting local analgesic approved for use in patients as young as six years old and for multiple nerve block techniques. The product’s extended release profile reduces opioid consumption and supports enhanced recovery pathways which are increasingly valued by hospitals and payers. ZILRETTA is the first and only extended release intra articular corticosteroid offering up to sixteen weeks of pain relief from a single injection. iovera° delivers a drug free nerve block that can be repeated without loss of efficacy and is supported by a growing body of clinical data showing reduced opioid use and improved function. The company also holds a strong intellectual property portfolio with patents covering its pMVL drug delivery technology its microsphere formulation for ZILRETTA and its cryogenic device design for iovera° extending protection well into the 2040s. Its early stage gene therapy pipeline built on a high capacity adenovirus platform offers potential first in class treatments for osteoarthritis and other degenerative conditions. Together these factors give Pacira BioSciences, Inc. a defensible position and the ability to command premium pricing relative to generic alternatives.

The company sells its products to a diverse set of customers that includes hospitals ambulatory surgery centers physician practices and specialty clinics. The primary buyers are healthcare professionals who influence pain management decisions such as anesthesiologists surgeons pharmacists physician assistants and nurse practitioners. Because the products require cold chain distribution and specialized handling the firm relies on a limited number of national wholesalers to move goods from its manufacturing sites to the point of care. As noted McKesson Drug Company Cardinal Health Inc. and AmerisourceBergen Health Corporation are the three largest wholesalers each contributing a double digit share of total revenue. In addition to these distributors Pacira BioSciences, Inc. maintains direct relationships with group purchasing organizations and integrated delivery networks that help secure formulary placement and reimbursement coverage. The firm also works with academic medical centers and community hospitals to generate real world evidence and to support education programs about non opioid pain management. While the majority of revenue flows through the wholesale channel the end users of EXPAREL ZILRETTA and iovera° are patients undergoing surgical procedures or suffering from osteoarthritis knee pain who benefit from the therapies administered by their treating physicians.